Clinical Research Platform for Molecular Testing, Treatment, Quality of Life and Outcome of Patients with Esophageal, Gastric or Gastroesophageal Junction Cancer Requiring Palliative Systemic Therapy
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
The registry aims to collect and analyse information on the antineoplastic treatment of patients with metastatic esophageal, gastric or gastroesophageal junction cancer, treated in palliative intention in daily routine practice in Germany.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Histologically proven stage IV (metastatic) ESCC, EAC, GAC or GEJAC
• Planned palliative systemic first-line therapy
• Age \>= 18 years
• Signed informed consent (IC)
‣ Patients answering questionnaires: IC before first therapy cycle
⁃ Patients not answering questionnaires: IC latest 4 weeks after start of first therapy cycle
Locations
Other Locations
Germany
Multiple sites, Gemany
RECRUITING
Multiple Locations
Contact Information
Primary
Adrian Binninger
info@iomedico.com
+49 761 152 42 - 0
Time Frame
Start Date: 2019-12-04
Estimated Completion Date: 2028-12-31
Participants
Target number of participants: 1900
Treatments
ESCC
250 patients with esophageal squamous cell carcinoma
GAC
920 patients with gastric adenocarcinoma
GEJAC
580 patients with gastroesophageal junction adenocarcinoma
EAC
150 patients with esophageal adenocarcinoma
Related Therapeutic Areas
Sponsors
Leads: iOMEDICO AG